In a strategic move set to reshape the future of cancer treatment, Eli Lilly and Company has announced its acquisition of Kelonia Therapeutics in a deal valued at up to $7 billion. The acquisition underscores Lilly’s growing commitment to genetic medicine and next-generation oncology solutions.Kelonia is pioneering an innovative in vivo gene delivery platform that enables the body to generate its own CAR-T cells—potentially eliminating the need for complex, lab-based cell manufacturing. Its lead candidate, KLN-1010, currently in early clinical development for multiple myeloma, has shown encouraging signs of efficacy and tolerability, drawing attention across the oncology community.
Unlike traditional CAR-T therapies, which are costly and time-intensive, Kelonia’s approach aims to offer a simpler, more accessible, “off-the-shelf” alternative. This could significantly expand patient access to life-saving treatments.The deal includes an upfront payment along with milestone-based payouts tied to clinical and commercial progress. Expected to close in the second half of 2026, the acquisition positions Lilly to accelerate innovation in cell therapy and broaden its oncology pipeline.As the race toward scalable cancer therapies intensifies, this move signals a pivotal shift toward more practical and patient-friendly CAR-T solutions.
